Low-Dose Triple-Pill Protocol Lowers BP in Black Africans With Hypertension
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 10, 2024 -- For Black African adults with uncontrolled hypertension, a low-dose triple-pill protocol achieves better blood pressure lowering and control than standard care, according to a study published online Aug. 31 in the Journal of the American Medical Association to coincide with the European Society of Cardiology Congress 2024, held from Aug. 30 to Sept. 2 in London.
Dike B. Ojji, Ph.D., from the University of Abuja in Nigeria, and colleagues compared the effectiveness and safety of a novel low-dose triple-pill protocol with a standard-care protocol for lowering blood pressure in a trial conducted in public hospital-based family medicine clinics in Nigeria. Black African adults with uncontrolled hypertension who were untreated or receiving a single blood pressure-lowering drug were randomly assigned to low-dose triple-pill or standard-care protocols. The triple-pill protocol involved a novel combination of telmisartan, amlodipine, and indapamide in triple one-quarter, one-half, and standard doses; the standard-care protocol started with amlodipine.
The researchers found that at month 6, mean home systolic blood pressure was on average 31 and 26 mm Hg lower in the triple-pill and standard-care protocols, respectively. At month 6, in the triple-pill and standard-care protocols, clinical blood pressure control was 82 and 72 percent, respectively, and home blood pressure control was 62 versus 28 percent, respectively. None of the participants discontinued treatment due to adverse events.
"The results demonstrate that the World Health Organization goal to achieve greater than 80 percent blood pressure control in those treated for hypertension is possible in low-income settings," the authors write.
Several authors disclosed ties to industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
2020 to 2023 Saw Increase in Buprenorphine Dispensing for Teens
THURSDAY, Dec. 26, 2024 -- Buprenorphine dispensing increased among adolescents and decreased among young adults between 2020 and 2023, according to a research letter published...
Prevalence of Post-COVID-19 Condition in Adults 8.4 Percent in 2023
THURSDAY, Dec. 26, 2024 -- The prevalence of post-COVID-19 condition (PCC) was 8.4 percent among U.S. adults in 2023, according to a research letter published online Dec. 13 in...
COVID-19 Infection Not Linked to Changes in MS Symptom Severity
THURSDAY, Dec. 26, 2024 -- COVID-19 infection is not associated with immediate changes in multiple sclerosis (MS) symptom severity or disability, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.